Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05208840
- Locations
- 🇷🇺
City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, Russian Federation
🇷🇺National Center of Socially Significant Diseases, Saint-Petersburg, Sankt Petersburg, Russian Federation
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT05199688
- Locations
- 🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇫🇷Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-bicêtre, France
🇦🇷Clinica Universitaria Reina Fabiola, Cordoba, Argentina
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05187624
- Locations
- 🇺🇸
UCLA Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT05181618
- Locations
- 🇲🇦
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
🇮🇹IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi", Milano, Lombardia, Italy
🇭🇺Észak-Pesti Centrumkórház - Honvédkórház; Országos Hemofília Központ, Budapest, Hungary
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 179
- Registration Number
- NCT05171777
- Locations
- 🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada
🇮🇹Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇰🇷Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT05171647
- Locations
- 🇺🇸
Ironwood cancer and research center, Chandler, Arizona, United States
🇺🇸City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco, California, United States
🇮🇹Irccs Ospedale San Raffaele;U.O. Oculistica, Milano, Lombardia, Italy
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05170204
- Locations
- 🇮🇳
Medanta-The Medicity, Gurgaon, Haryana, India
🇹🇷Dicle University Faculty of Medicine, Diyarbakir, Turkey
🇺🇸University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama, United States
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT05164133
- Locations
- 🇿🇦
Global Clinical Trials Sunnyside, Pretoria, South Africa
🇪🇸Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia, Esplugues de Llobregat, Barcelona, Spain
🇪🇸Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria, Madrid, Spain
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT05155345
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇵🇱Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
🇵🇱Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM; Oddzial Reumat Rehab i Chorob Wewnetrznych, Poznan, Poland